Twitter LinkedIn
    Friday, August 19
    Login
    0 Shopping Cart
    Twitter LinkedIn
    Private Equity InsiderPrivate Equity Insider
    • About Us
    • Digital Events
    • Our Network
      • Reach
      • Sponsors
      • Members
    Private Equity InsiderPrivate Equity Insider
    Home»Investments»Calixar invests EUR1m in pipeline of highly druggable membrane protein targets and native antigens
    Investments

    Calixar invests EUR1m in pipeline of highly druggable membrane protein targets and native antigens

    April 12, 20212 Mins Read
    LinkedIn Facebook Twitter Email WhatsApp
    Share
    LinkedIn Facebook Twitter Email WhatsApp

    Calixar, a biotechnology company with ten years expertise in the isolation of fully native membrane proteins, is to makes a EUR1 million (USD1.2 million) investment in a new pipeline of complex therapeutic targets and native antigens of high relevance for pharmaceutical companies

    This strategic investment, supported by Bpifrance investment bank, will enable the company to be the exclusive provider and licensor for pharmaceutical companies, with the best native and functional membrane therapeutic targets (GPCRs, ion channels, transporters, receptors and viral targets). It will also help them to discover the best drugs (small molecules and conformational antibodies) and develop the best vaccines.

    Drug development is becoming more costly and uncertain than ever (over USD1 billion – EUR0.9 billion – in 2020, with a 95 per cent failure rate). Only a few of the drugs authorised each year bring real health benefits. This is despite major scientific advances and ever-increasing investment, with over USD150 billion (EUR139 billion) invested annually worldwide (source: EvaluatePharma).

    Calixar was founded in 2011 with the aim of responding to those industry needs. It has developed its own unique technology, together with a research platform, in order to produce high-quality native membrane therapeutic targets that cover all therapeutic areas.

    Read more
    Source: Private Equity Wire

    Related

    Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.

    Capital deals and transactions Investments
    Share. LinkedIn Facebook Twitter Email WhatsApp

    Related Posts

    EQT makes buy-out offer for Karo Pharma

    August 18, 2022

    TA and Clearlake Capital-backed Kofax completes acquisition of Ephesoft

    August 18, 2022

    Apollo leads private equity interest in Manchester United stake

    August 18, 2022

    Blackstone announces Adam White, former President and COO of Bakkt, as Senior Advisor

    August 18, 2022

    Comments are closed.

    Other Articles

    Female-founded VC raises largest debut fund of USD1.5bn

    March 24, 2022

    Hertility Health pulls in £4.2m in seed funding

    June 15, 2021

    RCPDirect IV closes at $645.4m

    July 8, 2022

    Sprockets raises USD3.4m to bring AI to the hourly workforce

    January 14, 2021

    Private Equity Insider LLC
    1212 Avenue of the Americas
    New York City 10036
    USA

    [email protected]

    Twitter LinkedIn
    © 2022 Private Equity Insider LLC. All rights reserved.
    • About
    • Terms of Use
    • Cookie Policy
    • Privacy Policy
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.

    View Cart Checkout Continue Shopping

    Sign In or Register

    Welcome Back!

    Login to your account below.

    Lost password?